N'-[(E)-pentafluorophenylmethylidene]-2-phenoxybenzohydrazide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-[(E)-pentafluorophenylmethylidene]-2-phenoxybenzohydrazide
• 英文别名: N-[(E)-(2,3,4,5,6-pentafluorophenyl)methylideneamino]-2-phenoxybenzamide
• 化学式: C₂₀H₁₁F₅N₂O₂
• 分子量: 406.312
• InChiKey: VAMRZKDZHXYQBW-NSKAYECMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  五氟苯甲醛 、 2-苯氧基苯甲酰肼 以 乙醇 为溶剂， 反应 14.0h， 以71%的产率得到N'-[(E)-pentafluorophenylmethylidene]-2-phenoxybenzohydrazide
  参考文献：
  名称：

  SYNTHESIS AND ANALYSIS OF NOVEL COMPOUND CAPABLE OF INDUCING DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELL INTO HEPATOCYTE

  摘要：

  公开号：

  EP2698365B8

文献信息

• Inhibitory effect of low molecular weight compound on cancer and fibrosis
  申请人：NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

  公开号：US11213527B2

  公开（公告）日：2022-01-04

  A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.

  获得了一种治疗恶性肿瘤、癌症干细胞或纤维化的新型治疗药物。用于恶性肿瘤或癌症干细胞的治疗药物包括至少一种选自由式（1）、（2）和（5）所代表的化合物、其盐或其溶液组成的组中的化合物。另外，还可以使用一种治疗纤维化的药物，其中包括至少一种选自由式（1）、（2）和（5）所代表的化合物、其盐或其溶液组成的组中的化合物。
• INHIBITORY EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS
  申请人：NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY

  公开号：US20180028536A1

  公开（公告）日：2018-02-01

  A novel therapeutic drug for malignant tumors, cancer stem cells, or fibrosis is obtained. A therapeutic drug for malignant tumors or cancer stem cells is used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof. Alternatively, a therapeutic drug for fibrosis can be used that includes at least one compound selected from the group consisting of compounds represented by formulas (1), (2), and (5), a salt thereof, or a solvate thereof.
• US9555061B2
  申请人：——

  公开号：US9555061B2

  公开（公告）日：2017-01-31